Skip to content
Review Open access

Mechanism-Driven Evolution of Fertility-Sparing Treatment and Precision Management of Special Populations in Endometrial Cancer: A Review

Aug 2026 · Cancers · Vol 18, pp. 2741 · 0 citations · 43 references
Medicine

TL;DR

How fertility-sparing treatment has expanded from oral progestin therapy alone to include local intrauterine therapy, hysteroscopic lesion resection, metabolic interventions, combined endocrine therapy, and selected molecularly guided strategies is described.

Abstract

Simple Summary Endometrial cancer is increasingly affecting individuals who have not yet completed childbearing. For carefully selected patients with early-stage, low-risk disease, fertility-sparing treatment can preserve the uterus while the disease is closely monitored. However, responses to conventional progestin therapy vary, particularly among patients with obesity, polycystic ovary syndrome, abnormal glucose metabolism, Lynch syndrome, mismatch repair-deficient tumors, persistent disease, or recurrent disease. This review describes how fertility-sparing treatment has expanded from oral progestin therapy alone to include local intrauterine therapy, hysteroscopic lesion resection, metabolic interventions, combined endocrine therapy, and selected molecularly guided strategies. It also summarizes the patient populations most likely to benefit from each approach, their limitations, and the circumstances in which fertility-sparing treatment should be discontinued. Integrating pathological, metabolic, molecular, treatment-response, and reproductive factors may help clinicians better balance oncologic safety with the opportunity for future pregnancy.

Read PDF

Similar papers

Review Open access Sep 2026

Molecular classification of endometrial cancer in fertility-sparing-treatment: toward a personalized clinical approach

Current evidence suggests that NSMP tumors represent the most favorable subgroup for FST, showing the highest complete response rates and lowest recurrence rates, likely due to preserved estrogen and progesterone receptor signaling.

F. Ferrari, G. Bogani, M. Pavone et al. · 0 citations
Review Open access Sep 2026

Molecular groups predict response to fertility-sparing treatment of endometrial carcinoma: a systematic review and metanalysis.

BACKGROUND Molecular profiling has transformed endometrial carcinoma management, yet its value in predicting response to fertility-sparing conservative treatment remains undefined. OBJECTIVE To provide pooled estimates of oncologic outcomes of fertility-sparing treatment in women with early-stage endometrioid endomet...

A. Raffone, D. Neola, Angelica Tranchini et al. · 0 citations
Review Open access Aug 2026

THERAPEUTIC APPROACH AND TREATMENT STRATEGIES FOR PREMATURE OVARIAN INSUFFICIENCY

It is concluded that POI management must be individualized and multidisciplinary, based on an assessment of systemic risks, etiology, age, residual follicular activity, and the patient's reproductive goals.

Caren Andrigheti Grazziotin, Beatriz Donatelli Moro, Natália Passos Torres de Araújo et al. · 0 citations
Case report Open access Sep 2026

Case Report: Immunotherapy-containing fertility-sparing treatment integrated with preimplantation genetic testing resulting in live birth in Lynch syndrome-associated endometrial cancer

Background Lynch syndrome-associated endometrial cancer (LS-EC) presents unique challenges for fertility preservation. Conventional progestin-based therapy may be less effective in mismatch repair-deficient (MMRd) tumors, whereas immune checkpoint inhibitors (ICIs) have shown promising activity. Meanwhile, preimplantat...

Yan-Nan Zhao, Yue Zhao, Ting Hu et al. · 0 citations
Review Open access Oct 2026

Fertility Preservation for Reproductive-aged Women with Breast Cancer: A Contemporary Review

Breast cancer is the most common malignancy in reproductive-age women, and its incidence is rising fastest in those under 50 as early-stage survival exceeds 90%. This review synthesizes current evidence on fertility preservation in breast cancer, focusing on the safety, efficacy, and available options. Early referral f...

Samantha McLean, A. Herweck, M. Pavone · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.